215,725 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Bought by Jump Financial LLC

Jump Financial LLC bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 215,725 shares of the company's stock, valued at approximately $688,000. Jump Financial LLC owned about 0.32% of Perspective Therapeutics at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $33,000. Aigen Investment Management LP purchased a new position in Perspective Therapeutics in the fourth quarter worth $34,000. National Bank of Canada FI increased its position in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at $51,000. Finally, Trueblood Wealth Management LLC boosted its position in shares of Perspective Therapeutics by 37.0% in the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock worth $71,000 after purchasing an additional 6,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Perspective Therapeutics

In other news, Director Robert F. Williamson III bought 22,192 shares of the business's stock in a transaction dated Friday, March 28th. The stock was purchased at an average cost of $2.27 per share, with a total value of $50,375.84. Following the acquisition, the director now directly owns 70,837 shares in the company, valued at $160,799.99. This trade represents a 45.62 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Juan Graham bought 33,333 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average price of $2.25 per share, with a total value of $74,999.25. Following the completion of the purchase, the chief financial officer now owns 35,354 shares in the company, valued at approximately $79,546.50. This trade represents a 1,649.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 115,696 shares of company stock worth $256,344. Insiders own 3.52% of the company's stock.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $2.14 on Wednesday. The firm has a fifty day moving average price of $2.35 and a 200 day moving average price of $4.90. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $19.05.

Analysts Set New Price Targets

A number of research firms have commented on CATX. Royal Bank of Canada decreased their price target on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Truist Financial dropped their target price on shares of Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday, March 31st. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $12.75.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Want to see what other hedge funds are holding CATX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perspective Therapeutics, Inc. (NYSE:CATX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.